Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis.
OBJECTIVE
To report an 81-year-old woman with corneal neovascularization secondary to herpetic stromal keratitis treated with subconjunctival bevacizumab and to discuss the role of this novel antiangiogenic treatment.


METHODS
Case report and review of medical literature.


RESULTS
A dramatic regression of corneal vessels was observed 1 week after the injection. After a 3-month follow-up, there was no recurrence of corneal revascularization.


CONCLUSIONS
Bevacizumab may be a valid complementary treatment in patients with corneal neovascularization caused by herpetic stromal keratitis.
Carrasco
María Alejandra
MA
Centrovision Mendoza, National University of Cuyo, Mendoza, Argentina. macarras73@gmail.com
D000212:Acyclovir / Q000627:therapeutic use; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D003319:Corneal Stroma / Q000821:virology; D005260:Female; D006801:Humans; D016849:Keratitis, Herpetic / Q000150:complications* / Q000188:drug therapy; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000212:Acyclovir